If the response of duodenal adenocarcinoma was similar to that of colorectal cancer, angiogenesis inhibitors would be better than EGFR inhibitors for the treatment of duodenal adenocarcinoma with KRAS mutation. The gene discussed is KRAS; the disease is duodenal adenocarcinoma.